JP2003246730A - トリプターゼ阻害剤 - Google Patents

トリプターゼ阻害剤

Info

Publication number
JP2003246730A
JP2003246730A JP2002046613A JP2002046613A JP2003246730A JP 2003246730 A JP2003246730 A JP 2003246730A JP 2002046613 A JP2002046613 A JP 2002046613A JP 2002046613 A JP2002046613 A JP 2002046613A JP 2003246730 A JP2003246730 A JP 2003246730A
Authority
JP
Japan
Prior art keywords
tryptase
disease
mesylate
par
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002046613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003246730A5 (cg-RX-API-DMAC7.html
Inventor
Ryozo Oishi
了三 大石
Yoshinori Ito
善規 伊藤
Toshiaki Sendo
年昭 千堂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torii Pharmaceutical Co Ltd
Original Assignee
Torii Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torii Pharmaceutical Co Ltd filed Critical Torii Pharmaceutical Co Ltd
Priority to JP2002046613A priority Critical patent/JP2003246730A/ja
Priority to AU2003211540A priority patent/AU2003211540A1/en
Priority to TW092103438A priority patent/TW200306811A/zh
Priority to PCT/JP2003/001814 priority patent/WO2003070235A1/ja
Publication of JP2003246730A publication Critical patent/JP2003246730A/ja
Publication of JP2003246730A5 publication Critical patent/JP2003246730A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002046613A 2002-02-22 2002-02-22 トリプターゼ阻害剤 Pending JP2003246730A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002046613A JP2003246730A (ja) 2002-02-22 2002-02-22 トリプターゼ阻害剤
AU2003211540A AU2003211540A1 (en) 2002-02-22 2003-02-19 Medicinal compositions for inhibiting tryptase
TW092103438A TW200306811A (en) 2002-02-22 2003-02-19 Medicinal compositions for inhibiting tryptase
PCT/JP2003/001814 WO2003070235A1 (en) 2002-02-22 2003-02-19 Medicinal compositions for inhibiting tryptase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002046613A JP2003246730A (ja) 2002-02-22 2002-02-22 トリプターゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2003246730A true JP2003246730A (ja) 2003-09-02
JP2003246730A5 JP2003246730A5 (cg-RX-API-DMAC7.html) 2005-08-25

Family

ID=27750646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002046613A Pending JP2003246730A (ja) 2002-02-22 2002-02-22 トリプターゼ阻害剤

Country Status (4)

Country Link
JP (1) JP2003246730A (cg-RX-API-DMAC7.html)
AU (1) AU2003211540A1 (cg-RX-API-DMAC7.html)
TW (1) TW200306811A (cg-RX-API-DMAC7.html)
WO (1) WO2003070235A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120491A1 (ja) * 2004-06-14 2005-12-22 Torii Pharmaceutical Co., Ltd. 炎症性腸疾患の治療薬又は予防薬
WO2006123675A1 (ja) * 2005-05-17 2006-11-23 Santen Pharmaceutical Co., Ltd. アミジノ誘導体を有効成分として含む神経細胞の保護剤
JP2007186457A (ja) * 2006-01-13 2007-07-26 Ichimaru Pharcos Co Ltd トリプターゼ活性阻害剤およびその利用
JP2021512856A (ja) * 2018-02-09 2021-05-20 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB2445920A (en) * 2007-01-25 2008-07-30 Mucokinetica Ltd Amidino compounds for treatment of respiratory disease
CN106580961A (zh) * 2016-12-07 2017-04-26 郑州仁宏医药科技有限公司 一种用于治疗特发性肺纤维化的西药组合及其应用
CA3174067A1 (en) * 2020-03-31 2021-10-07 Lynn Kirkpatrick Methods for treating viral infections with nafamostat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5753454A (en) * 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
WO1997037969A1 (en) * 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120491A1 (ja) * 2004-06-14 2005-12-22 Torii Pharmaceutical Co., Ltd. 炎症性腸疾患の治療薬又は予防薬
WO2006123675A1 (ja) * 2005-05-17 2006-11-23 Santen Pharmaceutical Co., Ltd. アミジノ誘導体を有効成分として含む神経細胞の保護剤
JP2007186457A (ja) * 2006-01-13 2007-07-26 Ichimaru Pharcos Co Ltd トリプターゼ活性阻害剤およびその利用
JP2021512856A (ja) * 2018-02-09 2021-05-20 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
JP2024001032A (ja) * 2018-02-09 2024-01-09 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法

Also Published As

Publication number Publication date
AU2003211540A1 (en) 2003-09-09
TW200306811A (en) 2003-12-01
WO2003070235A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
EP1477166B1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
JPS6218401A (ja) 結合組織病理において有効な医薬の製造に使用する多糖およびオリゴ糖
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
CN1238693A (zh) 含有抗－Xa活性化合物和血小板聚集拮抗化合物的药物组合物
JPS6036414A (ja) 口鼻咽粘膜用医薬
CA2442761A1 (en) Drugs comprising chymase inhibitors and ace inhibitors as effective ingredients
EP2110132B1 (de) Verwendung von Deuteriumoxid als Elastase-Inhibitor
CN1170592C (zh) 美拉加林的新用途
JP2003246730A (ja) トリプターゼ阻害剤
BR112021006132A2 (pt) compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv
PT97061B (pt) Metodo para a utilizacao de tenidap como inibidor da activacao de colagenase e da actividade de mieloperoxidase
JPWO1997035609A1 (ja) 組織因子凝固系インヒビター含有血管新生阻害剤
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
JP2023500791A (ja) 敗血症及び敗血症様症候群の早期管理及び防止
JP2013518061A (ja) 疾患の治療に使用される化合物
EP4511031A1 (en) Treatment of neutrophilic dermatoses
KR20050074598A (ko) 트롬빈 억제제 멜라가트란을 포함하는 수성 약학 제제 및혈전색전증 치료에서 비강 투여에 의하여 사용하는 약제의제조에서의 상기 제제의 용도
US20250100963A1 (en) Sulfonated and phosphorylated aromatic molecules
AU729488B2 (en) Compositions and methods for administering integrin receptor antagonists
RU2402329C2 (ru) Применение триоксопиримидина для лечения и предупреждения воспалительных заболеваний бронхов
WO2023230593A1 (en) Ptp1b inhibitors for treating lung injury
Joo et al. The comparison of inflammatory mediator expression in gingival tissues from human chronic periodontitis patients with and without type 2 diabetes mellitus
US20230218594A1 (en) Therapeutic compounds, compositions, and methods of use thereof
TW200403988A (en) Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
CN1678307A (zh) 通过选择性磷酸二酯酶4抑制剂来治疗非过敏性鼻炎

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090303